Catastrophic Antiphospholipid Syndrome Market Report 2026

The catastrophic antiphospholipid syndrome market size has grown rapidly in recent years. It will grow from $4.16 billion in 2025 to $4.6 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to improved identification of antiphospholipid antibodies, wider adoption of anticoagulation therapy, increased reporting of rare autoimmune conditions, expansion of hospital-based intensive care capabilities, growing use of plasmapheresis in critical care.

The catastrophic antiphospholipid syndrome market size is expected to see rapid growth in the next few years. It will grow to $6.8 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing research on complement inhibitors, rising demand for targeted biologic treatments, expansion of rare disease clinical trials, growing use of precision diagnostics, increasing collaboration between specialty care centers. Major trends in the forecast period include expansion of precision immunotherapy approaches, growing use of combination treatment protocols, increasing focus on early and rapid diagnosis, rising clinical awareness of rare autoimmune disorders, development of targeted biologic therapies.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the catastrophic antiphospholipid syndrome market in the coming years. Autoimmune disorders are conditions in which the immune system mistakenly attacks the body’s own healthy cells and tissues. The rise in autoimmune disorders is partly attributed to greater exposure to environmental pollutants, which disrupt immune function and trigger abnormal immune responses. Autoimmune disorders contribute to catastrophic antiphospholipid syndrome by promoting the production of antiphospholipid antibodies, leading to widespread blood clotting and multi-organ failure. For instance, in June 2023, according to the Crohn's and Colitis Foundation of Canada, a Canada-based non-profit organization, approximately 322,600 people were living with inflammatory bowel disease in Canada in 2023, with projections rising to 470,000 by 2035 and annual new cases increasing from 11,000 to 14,000. Therefore, the rising prevalence of autoimmune disorders is fueling the growth of the catastrophic antiphospholipid syndrome market.

The increasing healthcare expenditure is expected to propel the growth of the catastrophic antiphospholipid syndrome market going forward. Healthcare expenditure refers to the total financial resources allocated to health services, medical goods, and public health activities by individuals, governments, and organizations. Healthcare spending is rising due to an aging population, as older individuals typically require more frequent and intensive medical care. Increased healthcare expenditure supports catastrophic antiphospholipid syndrome patients by providing access to advanced diagnostics, intensive care, and life-saving treatments such as anticoagulation therapy, immunosuppressants, and plasmapheresis. For instance, in June 2025, according to the Centers for Medicare & Medicaid Services, a US-based government agency, national health expenditures (NHE) grew by 7.5% in 2023, reaching $4.9 trillion - an average of $14,570 per person and 17.6% of GDP. Medicare spending increased by 8.1% to $1.02 trillion, accounting for 21% of total NHE. Therefore, the increasing healthcare expenditure is driving the growth of the catastrophic antiphospholipid syndrome market.

The rising number of clinical trials is expected to propel the growth of the catastrophic antiphospholipid syndrome market in the coming years. Clinical trials are research studies conducted in humans to evaluate the safety, effectiveness, and potential side effects of medical treatments or interventions. The increase in clinical trials is driven by the growing demand for personalized and innovative therapies that require rigorous testing for safety and efficacy. Clinical trials help improve the understanding, diagnosis, and treatment of catastrophic antiphospholipid syndrome by assessing new therapies, refining existing interventions, and guiding evidence-based clinical practices. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, the rising number of clinical trials is driving the growth of the catastrophic antiphospholipid syndrome market.

Major companies operating in the catastrophic antiphospholipid syndrome market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck KGaA, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Eli Lilly And Company, Boehringer Ingelheim International GmbH, Apotex Inc, Dr Reddys Laboratories Ltd, Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Limited, LEO Pharma AS, Kedrion Biopharma Inc, Amphastar Pharmaceuticals Inc, CSL Behring, Grifols SA, Octapharma AG, Baxter International Inc.

North America was the largest region in the catastrophic antiphospholipid syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the catastrophic antiphospholipid syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the catastrophic antiphospholipid syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the catastrophic antiphospholipid syndrome market by increasing costs of imported biologics, plasma-derived therapies, diagnostic reagents, and advanced laboratory equipment used in treatment and diagnosis. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported immunoglobulins and biologic drugs, while Asia-Pacific faces higher costs for specialized diagnostic technologies. These tariffs are raising treatment expenses and procurement timelines for critical therapies. However, they are also encouraging domestic biologics manufacturing, local plasma fractionation investments, and regional supply chain strengthening for rare disease therapeutics.

The catastrophic antiphospholipid syndrome market research report is one of a series of new reports that provides catastrophic antiphospholipid syndrome market statistics, including catastrophic antiphospholipid syndrome industry global market size, regional shares, competitors with a catastrophic antiphospholipid syndrome market share, detailed catastrophic antiphospholipid syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the catastrophic antiphospholipid syndrome industry. This catastrophic antiphospholipid syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening autoimmune disorder characterized by rapid and widespread blood clot formation in small vessels, resulting in multi-organ failure. It is triggered by antiphospholipid antibodies and often necessitates urgent treatment with anticoagulants, steroids, and immunosuppressive therapies.

The primary treatment options for catastrophic antiphospholipid syndrome include anticoagulants, immunosuppressive therapy, plasma exchange therapy (plasmapheresis), intravenous immunoglobulin (IVIG), and others. Anticoagulants are medications that help prevent or reduce blood clot formation by interfering with the clotting process. These treatments are administered either orally or parenterally. Diagnosis involves blood tests, imaging techniques, and genetic testing. These services are provided by various end users, including hospitals, specialty clinics, ambulatory surgical centers, and others.

The catastrophic antiphospholipid syndrome market consists of revenues earned by entities by providing services such as acute medical management, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The catastrophic antiphospholipid syndrome market also includes sales of antiphospholipid antibody test kits, anticoagulants, and immunosuppressive drugs. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.